The relaxin receptor as a therapeutic target - perspectives from evolution Cheek for updates and drug targeting
- 30 June 2018
- journal article
- review article
- Published by Elsevier BV in Pharmacology & Therapeutics
- Vol. 187, 114-132
- https://doi.org/10.1016/j.pharmthera.2018.02.008
Abstract
No abstract availableKeywords
Funding Information
- National Health and Medical Research Council of Australia (628427, 1043750, 1122170)
- Australian Research Council (LE120100022)
- NHMRC Research Fellowship (1042650)
- Natural Sciences and Engineering Research Council of Canada
- Norwegian Research Council (221648)
This publication has 179 references indexed in Scilit:
- Relaxin Prevents Cardiac Fibroblast-Myofibroblast Transition via Notch-1-Mediated Inhibition of TGF-β/Smad3 SignalingPLOS ONE, 2013
- The Minimal Active Structure of Human Relaxin-2Published by Elsevier BV ,2011
- R-spondins function as ligands of the orphan receptors LGR4 and LGR5 to regulate Wnt/beta-catenin signalingProceedings of the National Academy of Sciences of the United States of America, 2011
- Cyclic GMP signaling in cardiovascular pathophysiology and therapeuticsPharmacology & Therapeutics, 2009
- A relaxin-like peptide purified from radial nerves induces oocyte maturation and ovulation in the starfish, Asterina pectiniferaProceedings of the National Academy of Sciences of the United States of America, 2009
- Relaxin, a pleiotropic vasodilator for the treatment of heart failureHeart Failure Reviews, 2008
- Discovery and Validation of Novel Peptide Agonists for G-protein-coupled ReceptorsPublished by Elsevier BV ,2008
- The amphioxus genome and the evolution of the chordate karyotypeNature, 2008
- Origin of INSL3-mediated testicular descent in therian mammalsGenome Research, 2008
- The human LDL receptor: A cysteine-rich protein with multiple Alu sequences in its mRNACell, 1984